Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® (opens in new tab)
Organogenesis Holdings announced the completion of a rolling Biologics License Application (BLA) submission to the FDA for ReNu®, a cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee osteoarthritis (OA). The post Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® appeared first on Orthopedics This Week.
Read the original article